What is the recommended baclofen dosing regimen for treating persistent hiccups?

Baclofen Dosing for Persistent Hiccups

For persistent hiccups, start baclofen at 5 mg three times daily and increase to 10 mg three times daily (30 mg/day total) after 3 days, continuing for at least 5 days to assess response. 1, 2

Evidence-Based Dosing Regimen

The FDA-approved titration schedule for baclofen provides the foundation for hiccup treatment 1:

• Days 1-3: 5 mg three times daily (15 mg/day total)
• Days 4-7: 10 mg three times daily (30 mg/day total)
• Maintenance: Continue 10 mg three times daily if effective 2

The only randomized, double-blind, placebo-controlled trial specifically for hiccups in stroke patients used 10 mg three times daily for 5 days, achieving complete hiccup cessation in 93% of baclofen-treated patients versus 13% with placebo (relative risk 7.00,95% CI 1.91-25.62, P=0.003) 2. This represents the strongest evidence available for baclofen in hiccup management.

Treatment Duration and Response Assessment

• Initial trial period: 5 days at 10 mg three times daily is sufficient to determine efficacy 2
• Chronic hiccups (>48 hours duration): May respond better to baclofen than acute hiccups, though overall success rates are modest at 35% in real-world practice 3
• Maximum dose: Do not exceed 80 mg daily (20 mg four times daily) per FDA labeling 1

Alternative Agents When Baclofen Fails

If baclofen at 30 mg/day for 5-7 days provides no benefit, consider 4, 5:

• Gabapentin: Start 300 mg three times daily, may increase to 1200-1800 mg/day in divided doses
• Metoclopramide: 10 mg three times daily (supported by randomized controlled trial data)
• Chlorpromazine: 25-50 mg three to four times daily (only FDA-approved agent for hiccups, but higher side effect burden)

Baclofen and gabapentin are preferred for long-term therapy due to lower risk of extrapyramidal side effects compared to neuroleptics 5.

Critical Safety Considerations

Renal impairment: Baclofen is 69-85% renally excreted; reduce dose in patients with elevated creatinine or creatinine clearance <50 mL/min 1, 6. Start at 5 mg twice daily in significant renal dysfunction 7.

Abrupt discontinuation: Never stop baclofen suddenly after prolonged use (>1-2 weeks). Withdrawal can cause hallucinations, seizures, delirium, and potentially death 1, 8. Taper by 5-10 mg every 3-7 days when discontinuing 8.

Neonatal withdrawal: If used during pregnancy, gradually taper and discontinue before delivery to prevent neonatal withdrawal symptoms (increased muscle tone, tremor, seizures) 1.

Common adverse effects: Drowsiness and dizziness occur in approximately 5% of patients at standard doses 2. These effects are dose-dependent and may limit titration 7.

Clinical Context and Pitfalls

• Underlying cause: Always investigate and treat the underlying etiology of hiccups (gastroesophageal reflux, gastric distention, CNS lesions, metabolic disturbances) as primary therapy 5
• Empiric reflux treatment: Consider a trial of proton pump inhibitor therapy, as gastroesophageal reflux is a common reversible cause 5
• Stroke patients: Baclofen has shown poor tolerability and limited benefit in general stroke populations for spasticity, but the hiccup trial data are more favorable 7, 2
• Real-world efficacy: A large retrospective study found only 35% of patients achieved hiccup palliation with baclofen, suggesting the controlled trial may overestimate real-world effectiveness 3

Treatment Algorithm

1. Rule out and treat reversible causes (reflux, medications, metabolic abnormalities) 5
2. Start baclofen 5 mg TID for 3 days 1
3. Increase to 10 mg TID (30 mg/day) and continue for 5-7 days 1, 2
4. If no response: Switch to gabapentin 300 mg TID or metoclopramide 10 mg TID 4, 5
5. If partial response: May cautiously increase baclofen to 15-20 mg TID (maximum 80 mg/day) 1
6. Once hiccups resolve: Taper baclofen gradually over 1-2 weeks rather than stopping abruptly 1

The evidence for baclofen in hiccups remains limited to one small positive RCT in stroke patients and mixed real-world data, but it represents a reasonable first-line pharmacologic option given its favorable safety profile compared to neuroleptics 2, 3, 4, 5.